Integrated Filing — IndAS



General information about company

Scrip Code 544866
NSE Symbol MOLBIO
MSEI Symbol NOTLISTED
ISIN INE869T01028
Name of company Molbio Diagnostics Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 05-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 02-11-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Half Yearly
Reporting Quarter Half yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Healthcare
Start date and time of board meeting 05-11-2026   15:36:00
End date and time of board meeting 05-11-2026   16:03:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 05-11-2026
Indicate Company website link for updated RPT policy of the Company www.molbiodiagnostics.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There is no default for the quarter ended September 30, 2026



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 64,825.70 64,825.70
Other income 533.90 533.90
Total income 65,359.60 65,359.60
2 Expenses
(a) Cost of materials consumed 22,629.30 22,629.30
(b) Purchases of stock-in-trade 921.20 921.20
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (78.20) (78.20)
(d) Employee benefit expense 3,932.20 3,932.20
(e) Finance costs 1,493.00 1,493.00
(f) Depreciation, depletion and amortisation expense 2,241.10 2,241.10
(f) Other Expenses
1 Other expenses 22,393.30 22,393.30
Total other expenses 22,393.30 22,393.30
Total expenses 53,531.90 53,531.90
3 Total profit before exceptional items and tax 11,827.70 11,827.70
4 Exceptional items 0.00 0.00
5 Total profit before tax 11,827.70 11,827.70
6 Tax expense
7 Current tax 3,041.30 3,041.30
8 Deferred tax (14.10) (14.10)
9 Total tax expenses 3,027.20 3,027.20
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 8,800.50 8,800.50
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 8,800.50 8,800.50
17 Other comprehensive income net of taxes 20.50 20.50
18 Total Comprehensive Income for the period 8,821.00 8,821.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,152.40 1,152.40
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 7.76 7.76
Diluted earnings (loss) per share from continuing operations 7.76 7.76
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 7.76 7.76
Diluted earnings (loss) per share from continuing and discontinued operations 7.76 7.76
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: 1. The Statement of unaudited standalone financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026 of Molbio Diagnostics Limited (the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on November 05, 2026. The statutory auditors have conducted a limited review of the above unaudited standalone financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026. 2. The Statement of unaudited standalone financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026 of the Company has been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 (the Act) read with the relevant rules thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 3. During the quarter and six months ended September 30, 2026, the Company has completed its Initial Public Offer (IPO) of 11,646,246 equity shares (includes employee reservation portion of 20,519 equity shares) of face value of Rs. 1 each at an issue price of Rs. 807 per equity share to investors and at an issue price of Rs. 731 per equity share to employees. The issue consisted of a fresh issue of 2,480,246 equity shares aggregating to Rs. 2,000.00 Million and an offer for sale of 9,166,000 equity shares by selling shareholders aggregating to Rs. 7,396.96 Million. The Company's equity shares were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on August 17, 2026. Further, out of the total proceeds of Rs. 2,000.00 Million raised through the fresh issue pursuant to IPO, the Company is in the process of utilisation of the proceeds towards the objects of the Offer as disclosed in the offer document and the unutilised proceeds are temporarily invested in fixed deposit and other bank balances. 4. The shareholders of the Company through a special resolution approved the ‘Employee Stock Option Plan 2025 (“ESOP 2025”/ “Plan”) for creation of ESOP pool of 2,819,000 options having face value of Rs. 1/- each. During the quarter ended September 30, 2026, the Company granted 854,480 options to the employees of the Company and its subsidiaries, of which 5,656 options have been forfeited. 5. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws, collectively referred to as the 'New Labour Codes'. The Company had assessed and disclosed the incremental impact of these changes, which has resulted in increase in gratuity liability by Rs. 23.15 Million and increase in leave liability (compensated absences) by Rs. 8.19 Million. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company had presented this incremental amount as exceptional item for the year ended March 31, 2026. The Company continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules thereto. 6. A survey under Section 133A of the Income-tax Act, 1961 (“IT Act”), was carried out at the premises of the Company, by the Income Tax authorities during the year ended March, 2024, followed by search closure visits on various dates to check the compliance with the provisions of the IT Act. The income tax department has subsequently sought certain information/ clarifications, which have been submitted by the Company. The department has raised tax demands aggregating to Rs. 208.71 Million plus interest and penalty, as applicable, vide assessment / reassessment order for the AY 2020-21 to 2024-25. In response to the same, the Company has made appeal to the Commissioner Income Tax (Appeals) along with rectification applications. Management believes that the Company has complied with all the applicable provisions of the IT Act with respect to its operations. The Company has paid an amount of Rs. 78.95 Million as at September 30, 2026 under protest in connection with the survey. The management of the Company is confident of favourable outcome and accordingly no adjustments have been made in the unaudited standalone financial results for the quarter and six months ended September 30, 2026 in this regard. 7. a. During the year ended March 31, 2025, the Company, OptraSCAN, Inc. (“OptraSCAN”), its promoters and other existing shareholders entered into a Stock Purchase Agreement. Pursuant to the agreement, the Company subscribed to 2,918,827 Series B preferred shares (no par value), representing a 19.68% equity interest in OptraSCAN, for a consideration of Rs. 415.52 Million (USD 4.90 Million). Accordingly, OptraSCAN became an associate of the Company. Further, during the year ended March 31, 2026, the Company subscribed to an additional 14,951,540 Series B preferred shares (no par value) of OptraSCAN for a consideration of Rs.2,220.91 Million (USD 25.10 Million). Pursuant to this acquisition, effective November 01, 2025, the Company’s shareholding increased to 60%, resulting in OptraSCAN becoming a subsidiary of the Company. b. As at March 31, 2026, the Company held a stake of 65.47% in Prognosys Medical Systems Private Limited (PMS). During the quarter ended June 30, 2026, the Company acquired an additional stake of 4.53% in PMS from the existing shareholders. Consequently, the Company’s cumulative shareholding in PMS increased from 65.47% to 70.00%. 8. The operating segment of the Company is identified to be manufacturing of diagnostic devices, chips, reagents, etc and the Chief Operating Decision Maker reviews business performance at an overall company level constituting a single segment. Therefore, the disclosure as per Ind AS 108 Operating segments and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended is not applicable to the Company. 9. During the quarter ended September 30, 2025, the Company has allotted the bonus shares aggregating to 90,207,800 equity shares in accordance with Section 63 of the Act in the ratio of 4:1 i.e., 4 fully paid-up equity shares for every 1 equity share of face value of Rs. 1 each. In accordance with the provision of Ind AS 33, Basic and Diluted EPS for the quater ended September 30, 2025 and six months ended September 30, 2025 have been adjusted restrospectively and presented accordingly. 10. The figures for the quarter ended September 30, 2025 represent the balancing figures between the unaudited figures for the six months ended September 30, 2025 and the unaudited figures for the quarter ended June 30, 2025, both of which were compiled by management. Neither the figures for the quarter ended September 30, 2025 and six months ended September 30, 2025 nor those for the quarter ended June 30, 2025 have been subjected to audit or review by the statutory auditors.



Remarks

Debt equity ratio Not applicable
Debt service coverage ratio Not applicable
Interest service coverage ratio Not applicable


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 21,698.70
Capital work-in-progress 1,585.80
Investment property 0.00
Goodwill 0.00
Other intangible assets 2,973.10
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 31,758.50
Trade receivables, non-current 0.00
Loans, non-current 1,400.00
Other non-current financial assets
1 Non-current financial assets 2,470.20
Total of other non-current financial assets 2,470.20
Total non-current financial assets 35,628.70
Deferred tax assets (net) 4,835.10
Other non-current assets
1 Non-current tax assets (net) 1,600.20
2 Other assets 5,715.30
Total of other non-current assets 7,315.50
Total non-current assets 74,036.90
2 Current assets
Inventories 39,195.40
Current financial asset
Current investments 0.00
Trade receivables, current 27,873.00
Cash and cash equivalents 26,625.20
Bank balance other than cash and cash equivalents 7,539.30
Loans, current 0.00
Other current financial assets
Total of other current financial assets 5,179.30
Total current financial assets 67,216.80
Current tax assets (net) 0.00
Other current assets
1 Other assets 15,648.40
Total of other current assets 15,648.40
Total current assets 1,22,060.60
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 1,96,097.50
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,152.40
Other equity 1,40,528.20
Total equity attributable to owners of parent 1,41,680.60
Non controlling interest
Total equity 1,41,680.60
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 18,272.20
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease liabilities 735.10
Total of other non-current financial liabilities 735.10
Total non-current financial liabilities 19,007.30
Provisions, non-current 0.00
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
1 Net employee defined benefit liabilities 442.40
Total of other non-current liabilities 442.40
Total non-current liabilities 19,449.70
Current liabilities
Current financial liabilities
Borrowings, current 5,753.20
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 2,133.50
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 15,746.80
Total Trade payable 17,880.30
Other current financial liabilities
1 Lease liabilities 371.50
2 Other financial liabilities 2,040.40
Total of other current financial liabilities 2,411.90
Total current financial liabilities 26,045.40
Other current liabilities 6,942.90
1 Net employee defined benefit liabilities 100.00
2 Other liabilities 6,842.90
Total of other current liabilities 6,942.90
Provisions, current 1,978.90
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 34,967.20
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 54,416.90
Total equity and liabilites 1,96,097.50
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 (i) Re-measurement gains / (losses) on defined benefit plan 27.40 27.40
Total Amount of items that will not be reclassified to profit and loss 27.40
2 Income tax relating to items that will not be reclassified to profit or loss 6.90 6.90
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 20.50 20.50



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,437.50
Adjustments for decrease (increase) in inventories (208.70)
Adjustments for decrease (increase) in trade receivables, current 8,104.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 0.00
Adjustments for decrease (increase) in other non-current assets (1,045.00)
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 3,547.60
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 2,241.10
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss (157.50)
Adjustments for provisions, current 687.50
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (135.30)
Adjustments for dividend income 0.00
Adjustments for interest income 377.50
Adjustments for share-based payments 120.60
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (5.40)
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 14,208.90
Net cash flows from (used in) operations 26,036.60
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 4,017.30
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 22,019.30
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 14.80
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 3.80
Purchase of property, plant and equipment 2,845.30
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 93.50
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 382.50
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (12,147.70)
Net cash flows from (used in) investing activities (14,528.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 20,000.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 731.90
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 9,380.90
Payments of lease liabilities 232.50
Dividends paid 0.00
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (1,427.40)
Net cash flows from (used in) financing activities 8,227.30
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 15,718.60
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 15,718.60
Cash and cash equivalents cash flow statement at beginning of period 10,906.60
Cash and cash equivalents cash flow statement at end of period 26,625.20





Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 17-08-2026
Amount Raised 20,000.00
Report filed for Quarter ended 30-09-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review
Comments of the auditors, if any
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1  Funding capital expenditure towards the setting up of infrastructure for a research and development facility and Center of Excellence which will be operated by the wholly-owned Subsidiary, Bigtec and connected office space for Company, Subsidiaries and Associate company NA 10,553.50 0.00 0.00 0.00
2  Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit NA 7,228.10 0.00 679.60 0.00
3 General Corporate Purposes NA 946.50 0.00 0.00 0.00


Signatory Details

Name of signatory DARSHAN RAGHUNATH KAREKAR
Designation of person Company Secretary and Compliance Officer
Place Verna - Goa
Date 05-11-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Molbio Diagnostics limited Prognosys Medical Systems Private Limited Subsidiary Company Interest received No 70.20 0.00 0.00
2 Molbio Diagnostics limited Prognosys Medical Systems Private Limited Subsidiary Company Purchase of goods or services No 160.00 0.00 0.00
3 Molbio Diagnostics limited Prognosys Medical Systems Private Limited Subsidiary Company Any other transaction Commission income on corporate guarantee No 16.60 49.50 0.00
4 Molbio Diagnostics limited Optrascan India Private Limited Subsidiary Company Interest received No 2.60 0.00 0.00
5 Molbio Diagnostics limited Optrascan India Private Limited Subsidiary Company Purchase of goods or services No 25.70 0.00 0.00
6 Molbio Diagnostics limited Optrascan India Private Limited Subsidiary Company Loan No 93.50 93.50 0.00
7 Molbio Diagnostics limited Bigtec Private Limited Subsidiary Company Sale of goods or services No 490.10 0.00 0.00
8 Molbio Diagnostics limited Bigtec Private Limited Subsidiary Company Purchase of goods or services No 57.60 0.00 0.00
9 Molbio Diagnostics limited Bigtec Private Limited Subsidiary Company Any other transaction Royalty expense No 6,115.10 3,858.40 4,967.60
10 Molbio Diagnostics limited Inventrom Private Limited Enterprise with common director Purchase of fixed assets No 1.80 0.00 0.00
11 Molbio Diagnostics limited Inventrom Private Limited Enterprise with common director Any other transaction Repairs and Maintenance No 1.60 0.20 1.80
12 Molbio Diagnostics limited Coreintegra Global Services Private Limited Enterprise with common director Any other transaction Legal and Professional No 4.00 6.70 0.00
13 Molbio Diagnostics limited Coreintegra Consulting Services Limited Enterprise with common director Any other transaction Legal and Professional No 6.90 4.40 1.20
14 Molbio Diagnostics limited AmyGB.AI Private Limited Enterprise over which KMP exercise control or significant influence Any other transaction Repairs and Maintenance No 0.70 0.00 0.20
15 Molbio Diagnostics limited Prognosys Medical Systems Private Limited Subsidiary Company Loan No 0.00 1,400.00 1,400.00
16 Molbio Diagnostics limited Prognosys Medical Systems Private Limited Subsidiary Company Any other transaction Corporate Guarantee No 0.00 11,000.00 11,000.00
17 Molbio Diagnostics limited Prognosys Medical Systems Private Limited Subsidiary Company Any other transaction Fixed Deposi markes as lien for letter of credit issued to subsidiary No 0.00 1,000.00 0.00
18 Molbio Diagnostics limited Prognosys Medical Systems Private Limited Subsidiary Company Any other transaction Interest accrued refunded No 63.20 0.00 0.00
19 Molbio Diagnostics limited Optrascan India Private Limited Subsidiary Company Any other transaction Interest accrued refunded No 2.30 0.00 0.00
20 Molbio Diagnostics limited Bigtec Private Limited Subsidiary Company Any other transaction Expenses incurred on behalf of the Company No 0.50 0.00 0.00
21 Molbio Diagnostics limited Remfuel Bioenergy Private Limited Subsidiary Company Any other transaction Impairment on investments No 0.00 1.00 1.00
22 Molbio Diagnostics limited Bigtec Healthcare Private Limited Subsidiary Company Any other transaction Impairment on investments No 0.00 0.50 0.50
23 Molbio Diagnostics limited Prognosys Healthcare Private Limited Subsidiary Company Any other transaction Impairment on investments No 0.00 1,026.20 1,026.20
24 Molbio Diagnostics limited Deciphar Life Sciences Private Limited Subsidiary Company Any other transaction Impairment on investments No 0.00 1.10 1.10
25 Molbio Diagnostics limited Prognosys Medical Systems Private Limited Subsidiary Company Any other transaction Trade receivables No 0.00 5.50 0.00
Total value of transaction during the reporting period 7,112.40